Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | SORD | Q00796 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14161926 | 0.94 | KDM4E (0.50) | CHRM2CHRM4KDM4ESORDDPP4 | |
| SCHEMBL14161712 | 0.83 | MAP4K4 (0.47) | CHRM2CHRM4KDM4E | |
| SCHEMBL19035556 | 0.82 | HRH3 (0.51) | CHRM2CHRM4KDM4EDPP4DPP8 | |
| SCHEMBL4130328 | 0.81 | CHRM4 (0.47) | CHRM2CHRM4KDM4ESORDDPP4 | |
| SCHEMBL2320496 | 0.79 | SORD (0.51) | KDM4ESORDLMNAL3MBTL1GPR119 | |
| SCHEMBL31014265 | 0.79 | SORD (0.51) | KDM4ESORDLMNAL3MBTL1GPR119 | |
| SCHEMBL18228513 | 0.79 | SORD (0.51) | KDM4ESORDLMNAL3MBTL1GPR119 | |
| SCHEMBL4019738 | 0.79 | ROCK2 (0.48) | CHRM2CHRM4 | |
| SCHEMBL81925 | 0.78 | KCNH2 (0.42) | GPR119 | |
| SCHEMBL468382 | 0.77 | SORD (0.50) | KDM4ESORDLMNAL3MBTL1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301267-B2 | Compounds | ASTRAZENECA AB (SE) | 2019-05-28 | — | — | US | disclosed |
| US-20170260143-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | US | disclosed |
| US-9688640-B2 | Methods of treating cancer with a pyrazole derivative | ASTRAZENECA AB (SE) | 2017-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301267-B2 | Compounds | SLC10A1, CYP11B1, ABCB11 | CHRM2 4554/4885CHRM4 4739/4885KDM4E 2865/4885 |
| US-20170260143-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | CHRM2 4461/4885CHRM4 4662/4885KDM4E 3393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.